Laboratory of Microbiology and Immunology and the Global COE Program, University of Shizuoka School of Pharmaceutical Sciences, 52-1 Yada, Suruga-ku, Shizuoka, Shizuoka 422-8526, Japan.
Biol Pharm Bull. 2010;33(2):204-8. doi: 10.1248/bpb.33.204.
Lysophosphatidic acid (LPA) is a lipid mediator that is known to exhibit chemotactic activity toward a variety of cancer cells. However, its effect on the immune system has not been studied extensively. Another lipid mediator, sphingosine-1-phosphate (S1P), has been shown to influence lymphocyte recirculation by regulating lymphocyte egress from lymphoid organs. In this study, we found that LPA inhibits spontaneous migration of mouse splenic lymphocytes through a chemorepulsive effect. We also demonstrated that LPA inhibits chemokine CCL21-induced lymphocyte migration. This inhibitory effect on CCL21-induced migration was observed for both T and B cells. The involvement of a receptor, LPA(1), LPA(2) or LPA(3), in the inhibition of the CCL21-induced migration was confirmed with a synthetic agonist, oleyl thiophosphate. Considering that the signaling by CCL21 through cognate receptor CCR7 contributes to lymphocyte homing and dendritic cell trafficking to lymph nodes, LPA may play a role as a key regulator of these processes. The inhibitory effect of LPA is in remarkable contrast to the effect of S1P receptor signaling, which is known to potentiate lymphocyte chemotaxis involving CCR7.
溶血磷脂酸(LPA)是一种已知的脂质介质,它对多种癌细胞表现出趋化活性。然而,它对免疫系统的影响尚未得到广泛研究。另一种脂质介质,1-磷酸鞘氨醇(S1P),已被证明通过调节淋巴细胞从淋巴器官的迁出来影响淋巴细胞的再循环。在这项研究中,我们发现 LPA 通过趋化排斥作用抑制小鼠脾淋巴细胞的自发迁移。我们还证明 LPA 抑制趋化因子 CCL21 诱导的淋巴细胞迁移。这种对 CCL21 诱导迁移的抑制作用在 T 和 B 细胞中均观察到。使用合成激动剂油酰基硫代磷酸酯,证实了 LPA(1)、LPA(2)或 LPA(3)受体在抑制 CCL21 诱导的迁移中的参与。考虑到 CCL21 通过同源受体 CCR7 的信号传导有助于淋巴细胞归巢和树突状细胞向淋巴结的迁移,LPA 可能作为这些过程的关键调节剂发挥作用。LPA 的抑制作用与 S1P 受体信号传导的作用形成鲜明对比,后者已知可增强涉及 CCR7 的淋巴细胞趋化作用。